美国大型流感疫苗效果网络中季中估计的样本量考量
该研究基于美国流感疫苗效果网络八个季节的数据,采用合并的疫苗效果和年龄组疫苗覆盖率输入,计算估计季中疫苗效果所需的样本量。结果显示,在测试阴性对照中疫苗覆盖率为55%时,检测总体疫苗效果40%需135例流感阳性病例;针对甲型H3N2和老年组需更大样本。利用现有网络,美国近期多数流感季节可按所提样本量对宽年龄组进行有效的季中疫苗效果估计。
要点
- 检测总体VE 40%(疫苗覆盖率55%)需135例流感阳性病例。
- 针对甲型H3N2和老年组的可靠估计需要更大样本量。
- 利用现有网络,多数近期流感季节可按所提样本量进行宽年龄组季中VE估计。
核心结论
- 在测试阴性对照疫苗覆盖率为55%时,检测总体疫苗效果40%需135例流感阳性病例。
- 针对甲型H3N2和老年组的可靠估计需要更大样本量。
- 利用现有网络,美国近期多数流感季节可按所提样本量对宽年龄组进行有效的季中疫苗效果估计。
研究设计与样本
- 使用美国流感疫苗效果网络八个季节的数据,合并按(亚)型的疫苗效果和按年龄组的平均疫苗覆盖率作为输入,计算估计季中疫苗效果所需的样本量。
主要发现
- 检测总体疫苗效果40%(疫苗覆盖率55%)需135例流感阳性病例。
- 针对甲型H3N2和老年组的可靠估计需要更大样本量。
关键数值与推荐
- 检测总体VE 40%且疫苗覆盖率55%时,所需流感阳性病例数为135例。
临床怎么用
- 可利用现有流感疫苗效果网络,按所提样本量对宽年龄组进行季中疫苗效果估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Mid-season influenza vaccine effectiveness (VE) estimates are a useful tool to help guide annual influenza vaccine strain selection, vaccine policy, and public health messaging. We propose using a sample size-driven approach with data-driven inputs for publication of mid-season influenza VE. METHODS: We used pooled inputs for VE by (sub)type and average vaccine coverage by age groups using data from eight seasons of the US Influenza VE Network to calculate sample sizes needed to estimate mid-season VE. RESULTS: We estimate that 135 influenza-positive cases would be needed to detect an overall VE of 40% with 55% vaccine coverage among test-negative controls. Larger sample sizes would be required to produce reliable estimates specifically against influenza A/H3N2 and for older age groups. CONCLUSION: Using an existing network, most of the recent influenza seasons in the US would facilitate valid mid-season VE estimates using the proposed sample sizes for broad age groupings.
引用
- Chung JR, Flannery B, Kim SS, et al. Sample size considerations for mid-season estimates from a large influenza vaccine effectiveness network in the United States. Vaccine. 2021. PMID: 33994240. doi:10.1016/j.vaccine.2021.05.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。